Drug Profile
ISIS 13312
Latest Information Update: 19 Jul 2010
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Isis Pharmaceuticals; Novartis Ophthalmics
- Class Antisense oligonucleotides; Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 19 Jul 2010 Discontinued - Phase-II for Cytomegalovirus infections in USA (Ophthalmic)
- 10 Nov 1998 Suspended-II for Cytomegalovirus infections in USA (Ophthalmic)
- 08 Jan 1998 Phase-I clinical trials for Cytomegalovirus infections in USA (Unknown route)